Schrödinger Q4 software revenue $79.7M (+16% YoY); 2025 outlook: rev growth 10-15%, drug disc rev $45-50M

Schrodinger, Inc.

2024-FY EPS reported -$2.57 revenue$207,539,000

Q4 2024 total revenue $88.3M (+19% YoY); software revenue $79.7M (+16% YoY).
Full-year 2024 net loss $187.1M vs net income $40.7M in 2023; non-GAAP net loss $191.4M.
Cash, equivalents, and marketable securities $367.5M at Dec 31, 2024; received $150M upfront from Novartis in Jan 2025.
2025 guidance: software revenue growth 10-15%; drug discovery revenue $45-50M; software gross margin 74-75%; OpEx growth <5%.
Expanded collaboration with Lilly (undisclosed target); Novartis collaboration cleared with $150M payment received.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.